Netherlands· NL-ca318b323cf2
EVOTAZ 300 mg/150 mg filmomhulde tabletten
A atazanavir and cobicistat product containing atazanavirsulfaat + cobicistat, registered in Netherlands by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Atazanavir and cobicistat is registered in 11 of 19 countries.
Countries holding a registration under ATC J05AR15 (atazanavir and cobicistat), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Atazanavir and cobicistat · ATC J05AR15
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ATAZANAVIRSULFAAT + COBICISTAT
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Netherlands (NL)
- ATC code
- J05AR15
- ATC class
- Atazanavir and cobicistat
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/15/1025
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Atazanavir and cobicistat in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEVOTAZBristol-Myers Squibb Pharma EEIG, Dublin
- SpainEVOTAZ 300 MG/150 MG COMPRIMIDOS RECUBIERTOS CON PELICULABristol-Myers Squibb Pharma Eeig
- FinlandEVOTAZBristol-Myers Squibb Pharma EEIG
- United KingdomEvotaz 300mg/150mg tabletsBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandEVOTAZ 300 mg/150 mg film-coated tabletsBristol-Myers Squibb Pharma EEIG
- IcelandEvotazBristol-Myers Squibb Pharma EEIG*
- PolandEvotazBristol-Myers Squibb Pharma EEIG
- SwedenEVOTAZ 300 mg/150 mg Filmdragerad tablettBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Evotaz
- Liechtenstein · Evotaz
- Norway · Evotaz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4ade3e15-cc0c-46b9-ba7f-1f3a1759b05c GET /v1/drugs/4ade3e15-cc0c-46b9-ba7f-1f3a1759b05c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/evotaz-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Atazanavir and cobicistat",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp115908",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"CROSPOVIDON (E 1202)",
"GLYCEROLTRIACETAAT (E 1518)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE (E 464)",
"IJZEROXIDE ROOD (E 172)",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMZETMEELGLYCOLAAT",
"SILICIUMDIOXIDE (E 551)",
"STEARINEZUUR (E 570)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"ATAZANAVIRSULFAAT",
"COBICISTAT"
],
"leaflet_url": null,
"authorised_at": "2015/07/13",
"procedure_number": "EMEA/H/C/003904",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/15/1025",
"additional_monitoring": "N"
}See everything about atazanavir and cobicistat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.